Latest Sales Guidance News

TerraCom’s audited FY2026 results turned a previously reported A$45.6 million loss into a A$155.5 million statutory loss after A$103.5 million of non-cash impairments. The auditor highlighted material uncertainty over the company’s ability to continue as a going concern as Blair Athol remains below plan and new funding is not yet fully secured.

Zimi has secured an exclusive three-year distribution agreement with Directed for retail, direct-to-consumer and direct-to-business sales across Australia and New Zealand. The deal gives its next-generation Matter devices access to more than 10,000 retail outlets, although commercial terms and guaranteed sales volumes remain undisclosed.

ReNerve has converted regulatory approvals into its first commercial NervAlign Nerve Cuff surgeries in Hong Kong and Malaysia, expanding activity to seven jurisdictions. The milestones arrive as FY26 sales climbed 88% to $510,357 and the company builds out its US distribution network.

New Hope Group exceeded its FY26 coal production and sales guidance, driven by strong performances at Bengalla and New Acland mines, alongside a notable price uplift amid global supply tightness.

Neuren Pharmaceuticals saw a record Q2 with DAYBUE net sales hitting US$125 million, driven by strong uptake of the new STIX formulation. The company upgraded its 2026 royalty guidance following Acadia Pharmaceuticals’ sales boost and awaits key regulatory milestones in Europe and Japan.

KMD Brands expects a 5% rise in FY26 sales and a more than doubling of EBITDA, while planning to divest its Southeast Asian manufacturing facility over the next year.

29Metals reported a mixed June quarter with lower copper but higher zinc production at Golden Grove, steady safety metrics, and ongoing development progress including Xantho Extended mining restart and Gossan Valley first ore on track. Capricorn Copper's restart hinges on regulatory approval and a definitive feasibility study due by year-end.

Atomos Limited has trimmed its FY26 sales guidance to approximately $40 million due to softer end-consumer demand and delayed product shipments, while forecasting EBITDA between $2.5 million and $3.5 million supported by improved margins.

Northern Star Resources has met its revised FY26 gold sales guidance with a strong June quarter performance and remains on track with the KCGM mill expansion. The company also announced the appointment of Suresh Vadnagra as its next CEO, effective October 2026.

TerraCom signals operational recovery with improved coal sales guidance and cost reductions at Blair Athol, while advancing leadership appointments and strategic reviews.

Vita Life Sciences projects a slight increase in H1 2026 sales and stable pre-tax profits, supported by strong markets in Australia and Malaysia/Singapore but offset by regulatory headwinds in China.

Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.